EUVIMEDOdkrijte EUVIMED
Übersichtsarbeit

Natural compounds against nonalcoholic fatty liver disease: A review on the involvement of the LKB1 / AMPK signaling pathway

Navid Omidkhoda, Sina Mahdiani, A Wallace Hayes, Gholamreza Karimi iD

Phytotherapy Research · 2023-12 · 37 (12) · 5769-5786

DOI: 10.1002/ptr.8020 ↗

At a glance

Übersichtsarbeit in Phytotherapy Research, published online on 2023-09-25. Written by Navid Omidkhoda and 3 co-authors. Institution: Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease. Cited 16 times so far (Crossref); 159 references.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Although various therapeutic approaches are used to manage nonalcoholic fatty liver disease (NAFLD), the best approach to NAFLD management is unclear. NAFLD is a liver disorder associated with obesity, metabolic syndrome, and diabetes mellitus. NAFLD progression can lead to cirrhosis and end‐stage liver disease. Hepatic kinase B1 (LKB1) is an upstream kinase of 5′‐adenosine monophosphate‐activated protein kinase (AMPK), a crucial regulator in hepatic lipid metabolism. Activation of LKB1/AMPK inhibits fatty acid synthesis, increases mitochondrial β‐oxidation, decreases the expression of genes encoding lipogenic enzymes, improves nonalcoholic steatohepatitis, and suppresses NAFLD progression. One potential opening for new and safe chemicals that can tackle the NAFLD pathogenesis through the LKB1‐AMPK pathway includes natural bioactive compounds. Accordingly, we summarized in vitro and in vivo studies regarding the effect of natural bioactive compounds such as a few members of the polyphenols, terpenoids, alkaloids, and some natural extracts on NAFLD through the LKB1/AMPK signaling pathway. This manuscript may shed light on the way to finding a new therapeutic agent for NAFLD management.

Subjects

MeSH terms (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansAMP-Activated Protein KinasesLiverLipid MetabolismSignal Transduction

Author keywords

AMPKLKB1NAFLDNASH

Substances

AMP-Activated Protein Kinases

Authors and institutions

  • Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
  • College of Public Health, University of South Florida, Tampa, Florida, USA.
  • Institute for Integrative Toxicology, Michigan State University, East Lansing, Michigan, USA.
  • Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID profiles: Gholamreza Karimi

Cite

APA

Omidkhoda, N., Mahdiani, S., Hayes, A. W., & Karimi, G. (2023). Natural compounds against nonalcoholic fatty liver disease: A review on the involvement of the LKB1 / AMPK signaling pathway. Phytotherapy Research, 37(12), 5769-5786. https://doi.org/10.1002/ptr.8020

Vancouver

Omidkhoda N, Mahdiani S, Hayes AW, Karimi G. Natural compounds against nonalcoholic fatty liver disease: A review on the involvement of the LKB1 / AMPK signaling pathway. Phytotherapy Research. 2023;37(12):5769-5786. doi:10.1002/ptr.8020

BibTeX
@article{Omidkhoda2023,
  author = {Omidkhoda, Navid and Mahdiani, Sina and Hayes, A Wallace and Karimi, Gholamreza},
  title = {Natural compounds against nonalcoholic fatty liver disease: A review on the involvement of the LKB1 / AMPK signaling pathway},
  journal = {Phytotherapy Research},
  year = {2023},
  volume = {37},
  number = {12},
  pages = {5769--5786},
  doi = {10.1002/ptr.8020}
}
Start for free →